A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 33
Summary
- Conditions
- Melanoma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02382549
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Elizabeth Gaughan, MD University of Virginia Study Director: Craig L. Slingluff, Jr., MD University of Virginia
Get Well Soon